Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

ClinicalTrials.gov ID: NCT03333057

Public ClinicalTrials.gov record NCT03333057. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will evaluate the efficacy, safety and tolerability of perfluorohexyloctane (NOV03) at two different dosing regimens compared to saline solution in subjects with Dry Eye Disease (DED).

Study identification

NCT ID
NCT03333057
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novaliq GmbH
Industry
Enrollment
336 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 3, 2018 (Actual)
Primary completion
May 18, 2018 (Actual)
Completion
Jul 27, 2018 (Actual)
Last update posted
Jan 4, 2022

2018

United States locations

U.S. sites
11
U.S. states
6
U.S. cities
9
Facility City State ZIP Site status
Investigational site Artesia California 90701 —
Investigational Site Newport Beach California 92660 —
Investigational Site Newport Beach California 92663 —
Investigational Site Santa Ana California 92705 —
Investigational Site Torrance California 90505 —
Investigational site Jacksonville Florida 32256 —
Investigational Site Lake Villa Illinois 60046 —
Investigational Site Kansas City Missouri 64111 —
Investigational Site Pennington New Jersey 08534 —
Investigational Site Nashville Tennessee 37205 —
Investigational Site Nashville Tennessee 37215 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03333057, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 4, 2022 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT03333057 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →